This data dictionary describes the CLUSTER MTX clinical dataset. It contains key variables of interest for measuring treatment response to methotrexate (MTX) in juvenile idiopathic arthritis (JIA) patients at baseline/timepoint 1 (start of MTX treatment or up to 3 months before) and timepoint 2 (6 months after baseline, within a 3-12 month window). If a patient had multiple visits within a timepoint window, the one closest to baseline/6 months was selected. There are 2899 patients in this dataset. CLUSTER has brought together data from 4 UK observational JIA research cohort studies: the UK JIA Biologics Register, the Childhood Arthritis Prospective Study (CAPS) and the Childhood Arthritis Response to Medication Study (CHARMS). Clinical data...
Methotrexate (MTX) has transformed the outlook for children with juvenile idiopathic arthritis (JIA)...
OBJECTIVES: To assess if the Juvenile Arthritis Disease Activity Score (JADAS71) could be used to co...
BackgroundThe availability of methotrexate and the introduction of multiple biological agents have r...
This data dictionary describes the CLUSTER MTX clinical dataset. It contains key variables of intere...
This data dictionary describes the CLUSTER anti-TNF clinical dataset. It contains key variables of i...
This data dictionary describes the CLUSTER anti-TNF clinical dataset. It contains key variables of i...
Abstarct Analysis of the Therapy in Patients with Juvenile Idiopathic Arthritis Author: Martina Proc...
Abstarct Analysis of the Therapy in Patients with Juvenile Idiopathic Arthritis Author: Martina Proc...
Objectives Methotrexate (MTX) is a cheap and effi cacious drug in juvenile idiopathic arthritis (JIA...
Objective: Adalimumab (ADA) has become a valuable treatment option for juvenile idiopathic arthritis...
Background: The availability of methotrexate and the introduction of multiple biological agents have...
OBJECTIVE: The MARTE study investigated the demographic, clinical, and therapeutic characteristics o...
Background: The availability of methotrexate and the introduction of multiple biological agents have...
Background: The availability of methotrexate and the introduction of multiple biological agents have...
BACKGROUND: The MARTE study investigated the demographic, clinical, and therapeutic characteristics ...
Methotrexate (MTX) has transformed the outlook for children with juvenile idiopathic arthritis (JIA)...
OBJECTIVES: To assess if the Juvenile Arthritis Disease Activity Score (JADAS71) could be used to co...
BackgroundThe availability of methotrexate and the introduction of multiple biological agents have r...
This data dictionary describes the CLUSTER MTX clinical dataset. It contains key variables of intere...
This data dictionary describes the CLUSTER anti-TNF clinical dataset. It contains key variables of i...
This data dictionary describes the CLUSTER anti-TNF clinical dataset. It contains key variables of i...
Abstarct Analysis of the Therapy in Patients with Juvenile Idiopathic Arthritis Author: Martina Proc...
Abstarct Analysis of the Therapy in Patients with Juvenile Idiopathic Arthritis Author: Martina Proc...
Objectives Methotrexate (MTX) is a cheap and effi cacious drug in juvenile idiopathic arthritis (JIA...
Objective: Adalimumab (ADA) has become a valuable treatment option for juvenile idiopathic arthritis...
Background: The availability of methotrexate and the introduction of multiple biological agents have...
OBJECTIVE: The MARTE study investigated the demographic, clinical, and therapeutic characteristics o...
Background: The availability of methotrexate and the introduction of multiple biological agents have...
Background: The availability of methotrexate and the introduction of multiple biological agents have...
BACKGROUND: The MARTE study investigated the demographic, clinical, and therapeutic characteristics ...
Methotrexate (MTX) has transformed the outlook for children with juvenile idiopathic arthritis (JIA)...
OBJECTIVES: To assess if the Juvenile Arthritis Disease Activity Score (JADAS71) could be used to co...
BackgroundThe availability of methotrexate and the introduction of multiple biological agents have r...